Literature DB >> 28748816

Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma.

Yi-Chun Chu1, Ke-Chin Fang1, Hsing-Chun Chen1, Yi-Chen Yeh2, Chih-En Tseng3, Teh-Ying Chou4, Chun-Liang Lai5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28748816     DOI： 10.1016/j.jtho.2017.03.012

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  26 in total

1.  Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Authors:  Alessandro Inno; Nicola Maurea; Giulio Metro; Andreina Carbone; Antonio Russo; Stefania Gori
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

Review 2.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

4.  Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.

Authors:  Gregory R Stroh; Tobias Peikert; Patricio Escalante
Journal:  Cancer Immunol Immunother       Date:  2021-03-26       Impact factor: 6.968

5.  Mycobacterium avium complex lung disease in a patient treated with an immune checkpoint inhibitor: A case report.

Authors:  Yusuke Yamaba; Osamu Takakuwa; Yusaku Tomita; Sota Owaki; Kazuki Yamada; Eiji Kunii; Yutaka Ito; Kyoji Senoo; Kenji Akita
Journal:  Mol Clin Oncol       Date:  2021-12-17

6.  PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques.

Authors:  Keith D Kauffman; Shunsuke Sakai; Nickiana E Lora; Sivaranjani Namasivayam; Paul J Baker; Olena Kamenyeva; Taylor W Foreman; Christine E Nelson; Deivide Oliveira-de-Souza; Caian L Vinhaes; Ziv Yaniv; Cecilia S Lindestam Arleham; Alessandro Sette; Gordon J Freeman; Rashida Moore; Alan Sher; Katrin D Mayer-Barber; Bruno B Andrade; Juraj Kabat; Laura E Via; Daniel L Barber
Journal:  Sci Immunol       Date:  2021-01-15

7.  Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab.

Authors:  Naohiro Uchida; Kohei Fujita; Koichi Nakatani; Tadashi Mio
Journal:  Respirol Case Rep       Date:  2017-12-22

Review 8.  The dark side of immunotherapy.

Authors:  Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal:  Ann Transl Med       Date:  2021-06

Review 9.  Immune Checkpoint Inhibitors in Special Populations.

Authors:  Qianyun Shan; Hongyang Lu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

10.  Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.

Authors:  Shagufta Shaheen; Hamid Mirshahidi; Gayathri Nagaraj; Chung-Tsen Hsueh
Journal:  Exp Hematol Oncol       Date:  2018-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.